Delivery Order SPE2DB24D1205-SPE2DB25FCWYA
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,413.60 on August 25, 2025, for the supply of Xcopri 200 mg tablets (30-count). The contract is classified as a firm fixed price delivery order with an ultimate completion date of August 26, 2025, and represents a non-competitive set-aside award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is the place of performance for this order. This delivery order is issued under the company's...
- The Defense Logistics Agency awarded a $4,857.44 delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Xcopri 50 mg tablets (30-count units). This firm fixed-price contract, with an ultimate completion date of June 2, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The contract was competitively awarded with no...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Xcopri 100 mg tablets (30-count packaging) valued at $1,037.97. This firm fixed-price delivery order, with an ultimate completion date of August 18, 2025, represents a competitively awarded contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Xcopri 50 mg tablets (30-count) with a ceiling value of $1,182.13. This firm fixed-price delivery order, set to complete by August 1, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract involves no set-aside designation, indicating it was competitively awarded through open competition....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xcopri 200 mg tablets (30-count units) on May 20, 2025, with an ultimate completion date of May 21, 2025. This firm fixed-price delivery order, valued at $1,768.44, represents a non-set-aside competitive award and will be performed at the contractor's Conshohocken, Pennsylvania facility. The contract is issued as a child order under AmerisourceBergen's larger pharmaceutical supply vehicle...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Xcopri 25 mg tablets in a 30-count package. This firm fixed price delivery order, valued at $1,769.31, represents a non-set-aside competitive award with an ultimate completion date of September 4, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed...
- The Defense Logistics Agency awarded a delivery order valued at $1.77K to AmerisourceBergen Drug Corp on July 9, 2025, for the supply of Xcopri 100 mg tablets (30-count units). This is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded contract under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the contractor's corporate office location in Conshohocken, Pennsylvania, with an...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,080.32 on September 2, 2025, for the supply of Xcopri 200 mg tablets (30-count units). This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The contract was issued as a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99...
- The Defense Logistics Agency awarded a $2,232.99 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 30 tablets of Xcopri 200 mg on July 28, 2025, with completion targeted for July 29, 2025. This non-set-aside contract represents a pharmaceutical supply delivery to support federal medical procurement needs, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is issued as a child contract under AmerisourceBergen's...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $3,809.28 by the Defense Logistics Agency (DLA) on September 15, 2025, for the supply of Xcopri 200 mg tablets (30-count packaging). This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 16, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCWYADelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 20, 2025, for the supply of Xcopri 200 mg tablets (30-count units) under a firm fixed-price contract valued at $2,820.90. This is a non-set-aside award, indicating the contract was competitively awarded. The delivery order is associated with AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of May 21, 2025. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency. The company's role under the SPE2DX contract encompasses the delivery of a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, and related medical commodities across multiple therapeutic domains. This delivery order for Xcopri represents one of numerous transactions fulfilled through the company's expansive federal contract portfolio with DLA, demonstrating its ongoing capability to meet military healthcare pharmaceutical supply requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.8k | 5/20/25 |